Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions

Abstract Approximately 185 million people worldwide are chronically infected with hepatitis C virus (HCV). The first-wave of approved NS3 protease inhibitors (PIs) were Telaprevir and Boceprevir, which are currently discontinued. Simeprevir is a second-wave PI incorporated into the Brazilian hepatit...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Luciana Santos Pessoa, Luãnna Liebscher Vidal, Emmerson C.B. da Costa, Celina Monteiro Abreu, Rodrigo Delvecchio da Cunha, Ana Luiza Chaves Valadão, André Felipe dos Santos, Amilcar Tanuri
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Sociedade Brasileira de Genética
Saila:	Genetics and Molecular Biology
Gaiak:	protease inhibitor phenotypic test hepatitis C virus HCV NS3 protease resistance mutation
Sarrera elektronikoa:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572016000300358&lng=en&tlng=en
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!